Roche and Pfizer race to lead obesity and diabetes drug market with promising new treatments.

Roche Holding AG and Pfizer Inc. are aggressively developing new drugs targeting obesity and type 2 diabetes, aiming to capture growth in the GLP-1 market. Roche's enicepatide shows strong weight loss results in Phase 2 trials with a good safety profile, while Pfizer promotes its monthly-dosed berobenatide as potentially best-in-class based on meta-analysis, though it lacks direct clinical comparisons. The analyst favors Roche due to more comprehensive data and a broader pipeline, suggesting both companies could become major players in obesity treatment. This competition highlights the growing focus on cardiometabolic health in pharma portfolios.